Abstract
The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 213-217 |
| Number of pages | 5 |
| Journal | Journal of Molecular Neuroscience |
| Volume | 19 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Jan 1 2002 |
| Externally published | Yes |
Keywords
- Alzheimer's disease
- Beta-amyloid
- Indole-3-propionic acid
- Oxidative stress
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience
Fingerprint Dive into the research topics of 'Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease'. Together they form a unique fingerprint.
Cite this
Bendheim, P. E., Poeggeler, B., Neria, E., Ziv, V., Pappolla, M. A., & Chain, D. G. (2002). Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease. Journal of Molecular Neuroscience, 19(1-2), 213-217. https://doi.org/10.1007/s12031-002-0036-0